Once-weekly ALTUVIIIO® approved in Japan as a new class of factor VIII therapy for hemophilia A Post author: Post published:September 25, 2023 Post category:uncategorized The Japanese Ministry of Health, Labor, and Welfare (MHLW) has granted marketing authorization for ALTUVIIIO. You Might Also Like Food additive carrageenan (E 407) could disrupt the intestinal barrier and increase the risk of type 2 diabetes, study finds November 27, 2024 Light-activated therapy reduces antibiotic resistance in Staphylococcus aureus February 11, 2025 Rate of young women getting sterilized doubled after ‘Roe’ was overturned June 27, 2024
Food additive carrageenan (E 407) could disrupt the intestinal barrier and increase the risk of type 2 diabetes, study finds November 27, 2024